Science

Hung Trinh: An Ionizable Lipid Toolbox for RNA Delivery and the Rise of LNP-Based mRNA Vaccines

Hung Trinh/LinkedIn

Jun 9, 2025, 19:40

Hung Trinh: An Ionizable Lipid Toolbox for RNA Delivery and the Rise of LNP-Based mRNA Vaccines

Hung Trinh, Senior Director of Business Development at OBiO Tech, shared a post on LinkedIn about a paper by Michael J. Mitchell et al. published in Nature Communications:

“An ionizable lipid toolbox for RNA delivery

Before the approval of Onpattro in 2018, scientists had screened numerous ionizable lipids and LNP formulations for more than a decade. The success of MC3 has re-ignited the enthusiasm for RNA delivery and greatly accelerated the clinical development of other LNP-based RNA therapeutics, particularly mRNA vaccines (Fig. 2). Specifically, the COVID-19 pandemic has caused millions of deaths.

However, in less than one year, two LNP-based mRNA vaccines (mRNA-1273 and BNT162b2) underwent unprecedented speed of development and received the historic approval for emergency use after demonstrating protection efficacies above 94%43,44. Interestingly, Moderna’s SM-102 and BioNTech’s Acuitas ALC-0315 have some shared features, including a tertiary amine, branched tails, and ester linkers.

Moreover, both of them bear extended aliphatic branches, making them appear like multi-tailed structures. Currently, additional COVID-19 mRNA vaccines delivered by LNPs are undergoing clinical development. Although these ionizable lipid structures have not been publicly disclosed, the probable ones are shown based on available patents and literature.”

Title: An ionizable lipid toolbox for RNA delivery

Authors: Xuexiang Han, Hanwen Zhang, Kamila Butowska, Kelsey L. Swingle, Mohamad-Gabriel Alameh, Drew Weissman and Michael J. Mitchell

You can read the Full Article in Nature Communications.

More posts featuring Hung Trinh.

cancer Drew Weissman Hanwen Zhang Hung Trinh Kamila Butowska Kelsey L. Swingle Michael J. Mitchell Mohamad-Gabriel Alameh Nature Communications OncoDaily Oncology Onpattro RNA Delivery Xuexiang Han

How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening

Inside ASCO25 Exhibition - Who did it the best?

Douglas Flora: Fighting Cancer with Heart

Eric Small: Deeply Honored to Step Into the Role of 2025-26 ASCO President

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived